CDNA vs JNJ: fair value comparison
CareDx, Inc. and Johnson & Johnson · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, JNJ currently sits closer to the top of our ranking by discount to fair value. CDNA carries the stronger quality grade.
| CDNA | JNJ | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $64.00 | $261.44 |
| 12-month range | $14.28–$69.85 | $186.00–$278.43 |
| Rank by discount to fair value | #94 of 108 Healthcare | #87 of 108 Healthcare |
| Quality grade | A | D |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CDNA fair value analysis · JNJ fair value analysis